Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis

J Antimicrob Chemother. 1983 Aug;12(2):175-83. doi: 10.1093/jac/12.2.175.

Abstract

Fourteen children with cystic fibrosis and pulmonary lung infection due to Pseudomonas aeruginosa were treated with piperacillin (300 mg/kg/day) alone or piperacillin and tobramycin (7 mg/kg/day) iv. The outcome with respect to clinical state, chest X-ray and lung function tests was better with combination therapy than with piperacillin alone. Bacteriological response was the same with both regimens: leucocyte content of the sputum decreased, non-mucoid Ps. aeruginosa strains were eliminated, but mucoid strains were only suppressed (11 children). Peak serum levels of piperacillin averaged 102 mg/l, the overall serum elimination was 0.75 h and the mean sputum concentrations ranged from 1.07 to 2.2 mg/l. Peak serum levels of tobramycin averaged 5.15 mg/l, the half life was 1.25 h and the mean sputum concentrations ranged from 0.57 to 0.68 mg/l. The clearance of piperacillin and tobramycin was increased significantly. Drug-resistance did not develop during therapy.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Child
  • Cystic Fibrosis / complications*
  • Drug Therapy, Combination
  • Humans
  • Lung Diseases / drug therapy*
  • Lung Diseases / etiology
  • Piperacillin / administration & dosage
  • Piperacillin / therapeutic use*
  • Pseudomonas Infections / drug therapy*
  • Tobramycin / administration & dosage
  • Tobramycin / therapeutic use*

Substances

  • Tobramycin
  • Piperacillin